To build a multidisciplinary research program interacting with the research programs of Yale Cancer Center (YCC) and taking advantage of the shared YCC resources.
To develop a robust clinical/translational research program with high clinical trial accrual and impact on patient care.
To strive for scientific advancement in the field of Hematology in the hopes of bettering patient outcomes for those at Yale and beyond
Professor of Internal Medicine (Hematology); Chief, Hematologic Malignancies; Director, Early Therapeutics Research, Hematology; Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center; Chair, Protocol Review Committee (PRC) I, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Director, Hematology Research Seminar Series, Hematology; Member, Executive Committee, Yale Cancer Center; Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center
Amer Zeidan, MBBS, MHS is a Professor of Medicine at Yale School of Medicine. He serves as the Chief of the Division of Hematologic Malignancies, Director of Hematology Early Therapeutics Research, and Assistant Director of the Clinical Trial Office for Hematology at Yale Comprehensive Cancer Center (YCC). He is also the leader of Leukemia and Myeloid malignancies Clinical Research Team. Dr. Zeidan obtained his medical degree with honors from University of Jordan, followed by residency in Rochester General hospital, Rochester, NY. He then completed a Hematology/Oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He joined Yale Faculty in 2014 where he has become an internationally recognized expert in myeloid malignancies. Dr...
Assistant Professor of Medicine (Hematology); Assistant Professor of Medicine (Hematology), Internal Medicine
Curing hematologic cancers with precision medicine and minimal toxicity has been a multigeneration challenge and a highly prioritized work for our group at Yale. Through continual engagement with patients and their families, educational meetings and well informed decision making sessions, we help our patients navigate the field of transplantation and cellular therapy. Our multidisciplinary team while trying to harness the curative promise of cellular immunotherapy also has special focus to enhance its safety and provide long term supervision for cancer survivors. We strongly encourage our patients to learn the strengths and limitations of the existing standard of care, the knowledge of which could be applied to personalize treatment plans and foster research environment to advance the broader field.
Dr. Lourdes Mendez received her medical degree from Albert Einstein College of Medicine, as well as a PhD in Cell Biology. She completed her residency at Weill Cornell-New York Presbyterian and while a fellow in hematology/oncology at BIDMC, undertook a post-doctoral fellowship in cancer genetics. Most recently, Dr. Mendez was an Instructor of Medicine at Harvard Medical School and the Leukemia Disease Group Leader at BIDMC. She is currently a member of the Yale Leukemia Clinical and Research Team with a focus on clinical care and trials for patients with acute lymphoblastic leukemia. Dr. Mendez is dedicated to both the clinical care of patients and translational research with the goal of translating findings from the bench to the bedside to improve outcomes for patients with high-risk acute leukemia and precursor conditions (CHIP/CCUS).
Associate Professor of Internal Medicine (Hematology); Duffy Firm Chief for Education, Department of Internal Medicine; Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine; Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Dr. Nikolai Podoltsev is an Associate Professor of Medicine (Hematology). His practice is focused on management of patients with acute leukemias, including acute myeloid leukemias (AML) and acute lymphoblastic leukemia (ALL) as well as myeloid neoplasms like myelodisplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), and chronic myeloid leukemia (CML) among others. He also provides care for patients with aplastic anemia and bone marrow failure syndromes and follows patients with clonal hematopoiesis of indeterminate potential (CHIP), and systemic mastocytosis and hypereosinophilic syndrome. He is the director of the Hematology/Leukemia Tumor Board. As the Associate Director of the Yale Hematology/Oncology Fellowship Program and Yale-New Haven Hospital...
Professor of Internal Medicine (Hematology); Acting Director, Stem Cell Transplantation; Chairman, Car-T Cell Joint Steering Committee; Director, Unrelated Donor Transplant Program, Stem Cell Transplantation; Co-Director, Immune Effector Cell Therapy; Co-Director, Adult CAR T-Cell Therapy Program
Dr. Seropian is a Professor of Medicine in the department of Internal Medicine, Section of Hematology, Yale University School of Medicine. He received his medical degree from George Washington University School of Medicine and completed residency and fellowship training at Yale-New Haven Hospital/Yale University School of Medicine in 1996. Dr. Seropian serves as Interim Director of the Stem Cell Transplant Program, Co-Director, Immune Effector Cell Therapy, and Chairman, Car-T Cell Joint Steering Committee, Yale-New Haven Hospital. Dr. Seropian’s research interests include methods to improve the outcomes of transplantation through use of novel anti-cancer agents and new methods of treating graft versus host disease
Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital. He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS.Dr. Shallis also maintains research interest in epidemiological, outcomes and effectiveness research as it pertains to the hematologic malignancies with a goal of identifying barriers to effective care and ultimately strategies to improve the outcomes of patients with these malignant diseases. Dr. Shallis conducts...
Professor of Internal Medicine (Hematology); Chief, Hematologic Malignancies; Director, Early Therapeutics Research, Hematology; Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center; Chair, Protocol Review Committee (PRC) I, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Director, Hematology Research Seminar Series, Hematology; Member, Executive Committee, Yale Cancer Center; Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center
Amer Zeidan, MBBS, MHS is a Professor of Medicine at Yale School of Medicine. He serves as the Chief of the Division of Hematologic Malignancies, Director of Hematology Early Therapeutics Research, and Assistant Director of the Clinical Trial Office for Hematology at Yale Comprehensive Cancer Center (YCC). He is also the leader of Leukemia and Myeloid malignancies Clinical Research Team. Dr. Zeidan obtained his medical degree with honors from University of Jordan, followed by residency in Rochester General hospital, Rochester, NY. He then completed a Hematology/Oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He joined Yale Faculty in 2014 where he has become an internationally recognized expert in myeloid malignancies. Dr...